3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Rituximab
21
Cyclophosphamide
21
fludarabine
12
fludarabine phosphate
10
pirtobrutinib
6
obinutuzumab
6
ibrutinib
6
acalabrutinib
6
Tacrolimus
6
Mycophenolic Acid
6
Melphalan
6
Magnetic Resonance Spectroscopy
6
Biopsy
6
venetoclax
5
tocilizumab
5
X-Rays
5
Whole-Body Irradiation
5
Specimen Handling
5
Prednisone
5
Phantoms, Imaging
5
Peripheral Blood Stem Cell Transplantation
5
Nuclear Medicine Department, Hospital
5
Etoposide
5
Doxorubicin
5
Thiotepa
4
Lenalidomide
4
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
Cytarabine
4
Bendamustine Hydrochloride
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma, Non-Hodgkin
×
2019-nCoV Vaccine mRNA-1273
×
Clear all
NCT05556720
2025-10-03
BOOST-IC
Monash University
Phase 3
Active not recruiting
960 enrolled